Hematopoietic Stem Cell Transplantation Epidemiology

Hematopoietic Stem cell transplantation (HSCT) Insights and Trends

• Hematopoietic stem cell transplantation (HSCT) is a high-intensity cellular therapy that restores hematopoiesis and immune function through stem cell infusion following conditioning. It is applied across malignant and non-malignant diseases where conventional therapies fail to deliver durable control or cure.
• According to DelveInsight’s analysis, in 2025, the total number of HSCT procedures across the 7MM was around 55,000 cases, distributed unevenly across regions. Among the 7MM countries, EU4 and the UK accounted for the highest share, contributing around 47%, followed by the US at approximately 43%, while Japan represented about 10% of the total in 2025.
• In the US, the highest concentration of HSCT cases occurs in the 50 years and above age group with more than 15,000 cases in 2025, reflecting the increasing incidence of hematologic malignancies and transplant eligibility in older adults.
• Significant gaps persist, as relapse remains the primary cause of mortality in high-risk malignancies, often driven by pre-transplant MRD and immune escape mechanisms. Furthermore, acute and chronic GvHD continue to be dominant drivers of long-term morbidity, frequently requiring prolonged immunosuppression due to the lack of standardized maintenance protocols.

DelveInsight's ‘Hematopoietic Stem cell transplantation (HSCT)– Epidemiology Forecast – 2036’ report delivers an in-depth understanding of HSCT , historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• North America: The United States
• Europe: Germany, France, Italy, and Spain and the UK
• Asia-Pacific: Japan

Hematopoietic Stem cell transplantation (HSCT) Understanding

HSCT Overview

Hematopoietic stem cell transplantation (HSCT) is an advanced cellular therapy that restores hematopoiesis and immune function through stem cell infusion after conditioning therapy. It is used in hematologic malignancies and severe non-malignant disorders when conventional treatments fail to achieve durable disease control or cure. The HSCT approach is based on conditioning-driven disease eradication followed by stem cell engraftment, enabling regeneration of healthy blood and immune cells. Patient selection depends on disease risk, age, comorbidities, and transplant eligibility, as HSCT is an intensive procedure requiring specialized clinical management.

Autologous HSCT primarily supports dose-intensified chemotherapy using the patient’s own stem cells, offering lower immune complications and minimal graft-versus-host risk. In contrast, allogeneic HSCT uses donor stem cells and provides a graft-versus-disease effect, increasing curative potential but also introducing higher risks of immune toxicity, graft-versus-host disease, and long-term morbidity. Treatment pathways typically include stem cell mobilization and collection, conditioning regimens, stem cell infusion, and post-transplant immune management, with long-term monitoring focused on engraftment, relapse prevention, and immune recovery.

Further details are provided in the report.

Hematopoietic Stem cell transplantation (HSCT) Epidemiology

Key Findings from HSCT Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, in 2025, in the US, HSCT procedures were distributed across a range of indications, led by MM/PCDS (Multiple Myeloma/Plasma Cell Diseases) with more than 9,200 cases, followed by AML (Acute Myeloid Leukemia) with 16.5% of the cases, NHL (Non-Hodgkin Lymphoma) and MDS/MPN (Myelodysplastic Syndromes/Myeloproliferative Neoplasms) with 10.5%, ALL (Acute Lymphoblastic Leukemia) with 6.4% cases, HL (Hodgkin Lymphoma) with 4.6% cases, Other Malignant with 8.4% cases, and Non Malignant with 4.3% cases, reflecting the broad clinical application of HSCT across both malignant and non-malignant diseases.
• In 2025, EU4 and the UK reported more than 26,000 cases of HSCT, with Germany having the highest number at around 7,000 cases, whereas Spain had the fewest cases, which was nearly 4,000.
• According to DelveInsight, HSCT cases in the EU4 and the UK in 2025 were predominantly autologous HSCT with more than 15,000 cases, accounting for the majority of transplant procedures due to broader applicability and established treatment pathways.
• According to DelveInsight’s estimates, in 2025, in Germany, HSCT procedures by age were predominantly concentrated in older populations, with more than 700 cases in patients below 18 years, around 850 cases in the 18–34 years group, nearly 1,280 cases in the 35–49 years group, and about 4,250 cases in those aged 50 years and above, reflecting higher utilization among older patients.

Industry Experts and Physician Views for Hematopoietic Stem cell transplantation (HSCT)

To keep up with HSCT dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the HSCT epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Centers such as the Memorial Sloan Kettering Cancer Center, University of California San Francisco, State University of New York Upstate Medical University, etc. were contacted. Their opinion helps understand, validate, highlight and provide epidemiological context in HSCT.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of HSCT, explaining causes, signs, symptoms and pathogenesis of the diseases for which HSCT is indicated.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Report Insights

• Hematopoietic Stem Cell Transplantation (HSCT) Patient Population Forecast
• Country-wise Epidemiology Distribution
• Hematopoietic Stem Cell Transplantation (HSCT) Cases
• Hematopoietic Stem Cell Transplantation (HSCT) Cases by Indication
• Hematopoietic Stem Cell Transplantation (HSCT) Cases by Type
• Hematopoietic Stem Cell Transplantation (HSCT) Cases by Age
• Hematopoietic Stem Cell Transplantation (HSCT) Cases by Source

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year forecast
• Patient Burden Trends (by geography)
• The 7MM Coverage

FAQs

Epidemiology Insights

• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of HSCT cases?
• What are the disease risks and burdens of HSCT?
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of HSCT at the 7MM level?

Reasons to Buy

• The report will help in developing business strategies by understanding the latest epidemiology trends.
• Insights on patient burden/ prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand KOLs’ perspectives on the dynamic epidemiology trends.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.